OncoCyte Corp
OCX
Company Profile
Business description
OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers.
Contact
15 Cushing
IrvineCA92618
USAT: +1 949 409-7600
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
46
Stocks News & Analysis
video
Do you qualify as 'rich'?
Morningstar's Sim Mody speaks with Mark LaMonica about the varying definitions of rich.
stocks
Megatrend Investing: ASX players to capitalise on the clean energy transition
Find out how you can benefit from global megatrends.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,694.60 | 61.20 | 0.71% |
| CAC 40 | 7,906.40 | 51.48 | 0.66% |
| DAX 40 | 21,505.70 | 77.46 | 0.36% |
| Dow JONES (US) | 44,556.04 | 134.13 | 0.30% |
| FTSE 100 | 8,570.77 | 12.79 | -0.15% |
| HKSE | 20,659.34 | 130.62 | -0.63% |
| NASDAQ | 19,654.02 | 262.06 | 1.35% |
| Nikkei 225 | 38,746.44 | 51.93 | -0.13% |
| NZX 50 Index | 12,828.55 | 76.49 | -0.59% |
| S&P 500 | 6,037.88 | 43.31 | 0.72% |
| S&P/ASX 200 | 8,427.00 | 53.00 | 0.63% |
| SSE Composite Index | 3,238.85 | 11.75 | -0.36% |